Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
17 avr. 2024 01h15 HE
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
[Latest] Global Bispecific Antibodies Market Size/Share Worth USD 53.8 Billion by 2033 at a 24.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
04 avr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, April 04, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Bispecific Antibodies Market Size, Trends and Insights By Application (Cancer...
[Latest] Global Roasted Coffee Market Size/Share Worth USD 73.46 Billion by 2032 at a 5.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 févr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Roasted Coffee Market Size, Trends and Insights By Type (Arabica, Robusta), By...
GRI Bio Announces Reverse Stock Split
26 janv. 2024 08h05 HE
|
GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
05 janv. 2024 09h23 HE
|
Novartis Pharma AG
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility is the...
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
10 déc. 2023 19h30 HE
|
Novartis Pharma AG
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to...
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
08 déc. 2023 09h15 HE
|
Novartis Pharma AG
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...
Autonomix Medical, Inc. Announces Appointment of Christopher C. Capelli, M.D. to Board of Directors
16 nov. 2023 10h00 HE
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how...
[Latest] Global Disabled and Elderly Assistive Technology Market Size/Share Worth USD 66.84 Billion by 2030 at a 6.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate)
03 août 2023 15h30 HE
|
Custom Market Insights
Austin, TX, USA, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Disabled and Elderly Assistive Technology Market Size, Trends and Insights By...
Rapid Diagnostics Market to cross USD 79 billion by 2032, says Global Market Insights Inc.
27 juin 2023 04h00 HE
|
Global Market Insights Inc.
Selbyville, Delaware, June 27, 2023 (GLOBE NEWSWIRE) -- Rapid Diagnostics Market size is set to surpass USD 79 billion by 2032, given the rising awareness regarding early disease diagnosis among...